Back to today’s briefing

Story perspectives

Novo Nordisk Falls Behind as Eli Lilly Leads Obesity Race

6/5/2025

38 4

Summary

Story summary

Novo Nordisk, once at the forefront of obesity treatments with Wegovy, now finds itself lagging behind Eli Lilly. Former employees reveal that a cautious approach led to missed chances, including the abandonment of a promising triple agonist therapy. As Eli Lilly forges ahead with innovative obesity solutions, the competition intensifies in this lucrative market.

1 of 1

Story summary

Novo Nordisk, once at the forefront of obesity treatments with Wegovy, now finds itself lagging behind Eli Lilly. Former employees reveal that a cautious approach led to missed chances, including the abandonment of a promising triple agonist therapy. As Eli Lilly forges ahead with innovative obesity solutions, the competition intensifies in this lucrative market.